Applied Dna Sciences Inc (NASDAQ:APDN)’s traded shares stood at 0.47 million during the latest session, with the company’s beta value hitting 0.45. At the last check today, the stock’s price was $0.16, to imply an increase of 2.55% or $0.0 in intraday trading. The APDN share’s 52-week high remains $22.80, putting it -14150.0% down since that peak but still an impressive 12.5% since price per share fell to its 52-week low of $0.14. The company has a valuation of $8.39M, with an average of 6.63 million shares in intraday trading volume over the past 10 days and average of 4.45 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Applied Dna Sciences Inc (APDN), translating to a mean rating of 3.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give APDN a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.35.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Applied Dna Sciences Inc (NASDAQ:APDN) trade information
After registering a 2.55% upside in the latest session, Applied Dna Sciences Inc (APDN) has traded red over the past five days. The 5-day price performance for the stock is 8.28%, and -8.60% over 30 days. With these gigs, the year-to-date price performance is -98.66%. Short interest in Applied Dna Sciences Inc (NASDAQ:APDN) saw shorts transact 0.48 million shares and set a 0.11 days time to cover.
The extremes give us $1.5 and $1.5 for target low and target high price respectively. As such, APDN has been trading -837.5% off suggested target high and -837.5% from its likely low.
Applied Dna Sciences Inc (APDN) estimates and forecasts
Looking at statistics comparing Applied Dna Sciences Inc share performance against respective industry, we note that the company has outperformed competitors. Applied Dna Sciences Inc (APDN) shares are -69.48% down over the last 6 months, with its year-to-date growth rate higher than industry average at 88.16% against 12.00%. The rating firms project that company’s revenue will shrink -73.69% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is 899k. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 1.18M.Earnings reports from the last fiscal year show that sales brought in 779.74k and 891.16k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 15.29% before jumping 31.85% in the following quarter.
APDN Dividends
Applied Dna Sciences Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Applied Dna Sciences Inc (NASDAQ:APDN)’s Major holders
Applied Dna Sciences Inc insiders hold 0.62% of total outstanding shares, with institutional holders owning 0.50% of the shares at 0.50% float percentage. In total, 0.50% institutions holds shares in the company, led by MATHER GROUP, LLC. As of 2024-06-30, the company held over 700.0 shares (or 0.0803% of shares), all amounting to roughly $287.0.
We also have Fidelity Extended Market Index Fund and Fidelity Total Market Index Fund as the top two Mutual Funds with the largest holdings of the Applied Dna Sciences Inc (APDN) shares. Going by data provided on Sep 30, 2024, Fidelity Extended Market Index Fund holds roughly 58.73 shares. This is just over 0.12% of the total shares, with a market valuation of $9590.0. Data from the same date shows that the other fund manager holds a little less at 26.01, or 0.05% of the shares, all valued at about 4247.0.
